AU1449792A - A novel integrin specificity for the hiv tat protein - Google Patents

A novel integrin specificity for the hiv tat protein

Info

Publication number: AU1449792A
Authority: AU; Australia
Prior art keywords: binding; integrin; tat; hiv tat; tat protein
Prior art date: 1991-02-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU14497/92A

Other languages

English (en)

Inventor

Erkki I. Ruoslahti

Bruce E. Vogel

Flossie Y Wong-Staal

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of California

Sanford Burnham Prebys Medical Discovery Institute

Original Assignee

University of California

Sanford Burnham Prebys Medical Discovery Institute

La Jolla Cancer Research Foundation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-14

Filing date

1992-02-13

Publication date

1992-09-15

1992-02-13 Application filed by University of California, Sanford Burnham Prebys Medical Discovery Institute, La Jolla Cancer Research Foundation filed Critical University of California

1992-09-15 Publication of AU1449792A publication Critical patent/AU1449792A/en

Status Abandoned legal-status Critical Current

Links

108010044426 integrins Proteins 0.000 title claims description 160
102000006495 integrins Human genes 0.000 title claims description 160
108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 title claims description 36
101710149951 Protein Tat Proteins 0.000 claims description 205
230000027455 binding Effects 0.000 claims description 130
108090000765 processed proteins & peptides Proteins 0.000 claims description 94
239000012634 fragment Substances 0.000 claims description 42
238000000034 method Methods 0.000 claims description 37
239000003446 ligand Substances 0.000 claims description 25
239000003153 chemical reaction reagent Substances 0.000 claims description 23
150000007523 nucleic acids Chemical class 0.000 claims description 22
108020004707 nucleic acids Proteins 0.000 claims description 21
102000039446 nucleic acids Human genes 0.000 claims description 21
150000001413 amino acids Chemical class 0.000 claims description 19
239000000523 sample Substances 0.000 claims description 8
239000013598 vector Substances 0.000 claims description 7
230000009257 reactivity Effects 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 5
108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 claims description 4
230000000903 blocking effect Effects 0.000 claims description 4
108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
239000002853 nucleic acid probe Substances 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 5
210000004027 cell Anatomy 0.000 description 112
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 39
102000004196 processed proteins & peptides Human genes 0.000 description 36
108090000623 proteins and genes Proteins 0.000 description 23
235000018102 proteins Nutrition 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 22
108010031318 Vitronectin Proteins 0.000 description 20
102100035140 Vitronectin Human genes 0.000 description 20
229920002684 Sepharose Polymers 0.000 description 16
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
230000003993 interaction Effects 0.000 description 16
230000021164 cell adhesion Effects 0.000 description 14
102000005962 receptors Human genes 0.000 description 14
108020003175 receptors Proteins 0.000 description 14
238000001114 immunoprecipitation Methods 0.000 description 13
230000000694 effects Effects 0.000 description 12
239000000463 material Substances 0.000 description 12
238000001042 affinity chromatography Methods 0.000 description 11
230000006870 function Effects 0.000 description 11
241000725303 Human immunodeficiency virus Species 0.000 description 10
235000001014 amino acid Nutrition 0.000 description 9
238000003556 assay Methods 0.000 description 9
150000001875 compounds Chemical class 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
108010067306 Fibronectins Proteins 0.000 description 8
102000016359 Fibronectins Human genes 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 8
239000000284 extract Substances 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
108010053299 glycyl-arginyl-glycyl-aspartyl-seryl-proline Proteins 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
235000018417 cysteine Nutrition 0.000 description 6
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
238000001962 electrophoresis Methods 0.000 description 6
238000010828 elution Methods 0.000 description 6
239000000499 gel Substances 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
229920002401 polyacrylamide Polymers 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 6
239000000758 substrate Substances 0.000 description 6
102100022337 Integrin alpha-V Human genes 0.000 description 5
101500026036 Rattus norvegicus Neuropeptide W-23 Proteins 0.000 description 5
108010048673 Vitronectin Receptors Proteins 0.000 description 5
150000001768 cations Chemical class 0.000 description 5
230000001086 cytosolic effect Effects 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
NTEDOEBWPRVVSG-FQUUOJAGSA-N (2s)-1-[(2r)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](CO)C(=O)N1CCC[C@H]1C(O)=O NTEDOEBWPRVVSG-FQUUOJAGSA-N 0.000 description 4
208000007766 Kaposi sarcoma Diseases 0.000 description 4
239000013078 crystal Substances 0.000 description 4
108010064365 glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine Proteins 0.000 description 4
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 4
102000000844 Cell Surface Receptors Human genes 0.000 description 3
108010001857 Cell Surface Receptors Proteins 0.000 description 3
108010035532 Collagen Proteins 0.000 description 3
102000008186 Collagen Human genes 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
108010085895 Laminin Proteins 0.000 description 3
102000007547 Laminin Human genes 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
108091023040 Transcription factor Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
235000009697 arginine Nutrition 0.000 description 3
229920001436 collagen Polymers 0.000 description 3
230000008878 coupling Effects 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
238000005859 coupling reaction Methods 0.000 description 3
239000006274 endogenous ligand Substances 0.000 description 3
210000002744 extracellular matrix Anatomy 0.000 description 3
239000012133 immunoprecipitate Substances 0.000 description 3
235000018977 lysine Nutrition 0.000 description 3
239000000203 mixture Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
239000004475 Arginine Substances 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
208000018142 Leiomyosarcoma Diseases 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
101710162629 Trypsin inhibitor Proteins 0.000 description 2
229940122618 Trypsin inhibitor Drugs 0.000 description 2
238000007792 addition Methods 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
238000003352 cell adhesion assay Methods 0.000 description 2
210000005220 cytoplasmic tail Anatomy 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000012723 sample buffer Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
-1 t- butoxycarbonyl (BOC)-protected amino Chemical class 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
ZRVZOBGMZWVJOS-VMXHOPILSA-N (2s)-6-amino-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[2-[[(2s)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN ZRVZOBGMZWVJOS-VMXHOPILSA-N 0.000 description 1
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical class C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
108010089610 Nuclear Proteins Proteins 0.000 description 1
102000007999 Nuclear Proteins Human genes 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
102000004264 Osteopontin Human genes 0.000 description 1
108010081689 Osteopontin Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108700008625 Reporter Genes Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102000007000 Tenascin Human genes 0.000 description 1
108010008125 Tenascin Proteins 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
241000700605 Viruses Species 0.000 description 1
210000005221 acidic domain Anatomy 0.000 description 1
230000004913 activation Effects 0.000 description 1
102000019997 adhesion receptor Human genes 0.000 description 1
108010013985 adhesion receptor Proteins 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
150000001484 arginines Chemical class 0.000 description 1
230000008901 benefit Effects 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
230000009920 chelation Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000006471 dimerization reaction Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000011536 extraction buffer Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
108060004057 integrin beta chain Proteins 0.000 description 1
102000017776 integrin beta chain Human genes 0.000 description 1
238000002955 isolation Methods 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000003098 myoblast Anatomy 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002363 skeletal muscle cell Anatomy 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
108010047303 von Willebrand Factor Proteins 0.000 description 1
102100036537 von Willebrand factor Human genes 0.000 description 1
229960001134 von willebrand factor Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AU14497/92A 1991-02-14 1992-02-13 A novel integrin specificity for the hiv tat protein Abandoned AU1449792A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US65642491A	1991-02-14	1991-02-14
US656424		1991-02-14

Publications (1)

Publication Number	Publication Date
AU1449792A true AU1449792A (en)	1992-09-15

Family

ID=24632975

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU14497/92A Abandoned AU1449792A (en)	1991-02-14	1992-02-13	A novel integrin specificity for the hiv tat protein

Country Status (5)

Country	Link
EP (1)	EP0571549A4 (fr)
JP (1)	JPH06508603A (fr)
AU (1)	AU1449792A (fr)
CA (1)	CA2101919A1 (fr)
WO (1)	WO1992014755A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1991015224A1 (fr) *	1990-03-30	1991-10-17	Smithkline Beecham Corporation	Inhibition de la maladie associee a l'infection due au virus de l'immunodeficience
US6258550B1 (en)	1993-04-23	2001-07-10	Virginia Commonwealth University	Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
CA2215483C (fr) *	1995-03-08	2012-01-03	Jean-Francois Zagury	Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps, procede de preparation et compositions pharmaceutiques les renfermant
FR2731355B1 (fr) *	1995-03-08	1997-05-30	Neovacs	Nouveaux immunogenes, nouveaux anticorps, procede de preparation et compositions pharmaceutiques les renfermant
US6200575B1 (en)	1996-03-07	2001-03-13	Neovacs	Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them
US5891994A (en) *	1997-07-11	1999-04-06	Thymon L.L.C.	Methods and compositions for impairing multiplication of HIV-1
US6399067B1 (en)	2000-04-28	2002-06-04	Thymon L.L.C.	Methods and compositions for impairing multiplication of HIV-1
WO2006088740A2 (fr)	2005-02-15	2006-08-24	Thymon, L.L.C.	Methodes et compositions permettant d'alterer la multiplication de vih-1
WO2016118433A1 (fr)	2015-01-20	2016-07-28	Shayakhmetov Dmitry M	Variants d'adénovirus déciblés et procédés associés
US9982276B2 (en)	2015-03-12	2018-05-29	Adcure Biotechnologies, Llc.	Penton-mutated, integrin-retargeted adenovirus vectors with reduced toxicity and their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU3756789A (en) *	1988-06-16	1990-01-12	St. Louis University	Antagonists of viral transactivating proteins

1992
- 1992-02-13 EP EP92907398A patent/EP0571549A4/fr not_active Withdrawn
- 1992-02-13 WO PCT/US1992/001227 patent/WO1992014755A1/fr not_active Application Discontinuation
- 1992-02-13 JP JP4507307A patent/JPH06508603A/ja active Pending
- 1992-02-13 AU AU14497/92A patent/AU1449792A/en not_active Abandoned
- 1992-02-13 CA CA002101919A patent/CA2101919A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
JPH06508603A (ja)	1994-09-29
EP0571549A1 (fr)	1993-12-01
CA2101919A1 (fr)	1992-08-15
EP0571549A4 (fr)	1995-03-15
WO1992014755A1 (fr)	1992-09-03

Publication	Publication Date	Title
Vogel et al.	1993	A novel integrin specificity exemplified by binding of the alpha v beta 5 integrin to the basic domain of the HIV Tat protein and vitronectin.
US5817750A (en)	1998-10-06	Structural mimics of RGD-binding sites
Cheresh et al.	1989	Recognition of distinct adhesive sites on fibrinogen by related integrins on platelets and endothelial cells
US5268358A (en)	1993-12-07	PDGF receptor blocking peptides
US5589570A (en)	1996-12-31	Integrin alpha subunit cytoplasmic domain polypeptides and methods
US5705606A (en)	1998-01-06	Peptides derived from GPIIIa
CA2069902A1 (fr)	1991-06-02	Peptides et anticorps qui inhibent la liaison des integrines-ligands
AU1449792A (en)	1992-09-15	A novel integrin specificity for the hiv tat protein
Underwood et al.	1995	Evidence for the location of a binding sequence for the α 2 β 1 integrin of endothelial cells, in the β 1 subunit of laminin
US20080153756A1 (en)	2008-06-26	Novel Peptides and Methods for the Treatment of Inflammatory Disorders
US6482410B1 (en)	2002-11-19	Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making same
Ankenbauer et al.	1988	Proteins regulating actin assembly in oogenesis and early embryogenesis of Xenopus laevis: gelsolin is the major cytoplasmic actin-binding protein.
Cone et al.	1994	Effects of β subunit cytoplasmic domain deletions on the recruitment of the integrin αvβ6 to focal contacts
WO1996008513A9 (fr)	1996-05-17	Derives de cytotactine stimulant la connexion neuronale et la croissance des axones et des dendrites, leurs procedes de preparation et d'utilisation
US6124260A (en)	2000-09-26	Inhibition of smooth muscle cell migration by Tenascin-C peptides
EP1044012A1 (fr)	2000-10-18	Inhibition de l'angiogenese au moyen d'analogues de peptide du domaine 5 de la kininogene de poids moleculaire eleve
WO2001079144A2 (fr)	2001-10-25	Fyn kinase comme cible de modulation de la transduction des signaux medies par l'integrine
US7122324B2 (en)	2006-10-17	Vitro methods for determining in vivo thrombotic events
AU2323092A (en)	1993-02-11	Proteins s polypeptides and uses thereof
AU675073B2 (en)	1997-01-23	Methods and compositions for inhibiting endothelial cell and fibrinogen mediated inflammation
NZ512837A (en)	2003-08-29	Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs
WO1992007872A1 (fr)	1992-05-14	Peptides apparentes a la tenascine
CA2355968A1 (fr)	2000-06-29	Proteine et adn associe
US20090118174A1 (en)	2009-05-07	Novel peptides and methods for the treatment of inflammatory disorders